Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Change in Accured Expenses (2020 - 2025)

Lyell Immunopharma's Change in Accured Expenses history spans 6 years, with the latest figure at $572000.0 for Q3 2025.

  • For Q3 2025, Change in Accured Expenses fell 81.51% year-over-year to $572000.0; the TTM value through Sep 2025 reached -$13.8 million, down 695.39%, while the annual FY2024 figure was -$1.2 million, 73.85% down from the prior year.
  • Change in Accured Expenses for Q3 2025 was $572000.0 at Lyell Immunopharma, up from -$3.3 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $5.4 million in Q4 2022 and bottomed at -$9.8 million in Q1 2025.
  • The 5-year median for Change in Accured Expenses is $516000.0 (2024), against an average of -$549263.2.
  • The largest annual shift saw Change in Accured Expenses surged 396.08% in 2023 before it tumbled 745.35% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at $4.2 million in 2021, then rose by 27.41% to $5.4 million in 2022, then crashed by 132.37% to -$1.7 million in 2023, then grew by 27.89% to -$1.3 million in 2024, then soared by 145.61% to $572000.0 in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Change in Accured Expenses are $572000.0 (Q3 2025), -$3.3 million (Q2 2025), and -$9.8 million (Q1 2025).